Childhood asthma is a complex and heterogeneous disease. However, current treatment guidelines assume that it is a homogenous disease entity and advise universal treatment steps with similar medication for all children with asthma. Using this approach, about 10% of children with asthma do not respond to treatment (labelled ‘non-responders’), have severe symptoms and this increases their risk of dying from asthma.
Endotypes describe specific pathogenic mechanisms in the development of asthma and how they are linked to clinical presentation. This presentation will focus on endotype-driven treatment of asthma and its potential to improve outcomes of children with asthma. See attached poster for details.